Oxford University Press

SHERPA: Yellow

People

  1. Drilon
    Drilon
  2. Motzer
    Motzer
  3. Mellinghoff
    Mellinghoff
  4. Shuman
    Shuman
  5. Rosenblum
    Rosenblum
  6. Dunkel
    Dunkel
  7. Karajannis
    Karajannis
  8. Saltz
    Saltz
  9. Souweidane
    Souweidane
  10. Panageas
    Panageas

Groups

  1. Department of Medicine (1995)
  2. Solid Tumor Oncology Division (1624)
  3. GSK Faculty (765)
  4. Survivorship Research (639)
  5. Population Sciences Research Program (615)
  6. Epidemiology and Biostatistics (465)
  7. Department of Pathology and Laboratory Medicine (415)
  8. Gastrointestinal Oncology Service (386)
  9. Genitourinary Oncology Service (367)
  10. Tow Center for Developmental Oncology (TCDO) (352)
Search Within
Formats
  1. Journal Article (2107)
  2. Meeting Abstract (2072)
  3. Book Section (192)
  4. Review (92)
  5. Editorial (84)
  6. Guidelines (36)
  7. Correspondence (26)
  8. Book Whole (18)
  9. Conference Paper (15)
  10. Research Letter (10)
Groups
  1. Department of Medicine (1995)
  2. Solid Tumor Oncology Division (1624)
  3. GSK Faculty (765)
  4. Survivorship Research (639)
  5. Population Sciences Research Program (615)
  6. Epidemiology and Biostatistics (465)

More Groups

People
  1. Lisa De Angelis (119)
  2. Alexander Drilon (108)
  3. Robert Motzer (96)
  4. Ingo Mellinghoff (93)
  5. Stewart Shuman (88)
  6. Marc Rosenblum (87)

More People

Years
  1. 2025 (105)
  2. 2024 (304)
  3. 2023 (320)
  4. 2022 (331)
  5. 2021 (323)
  6. 2020 (325)

More Years

Publications
  1. Annals of Oncology (1670)
  2. Neuro-Oncology (846)
  3. JNCI: Journal of the National Cancer Institute (485)
  4. Nucleic Acids Research (210)
  5. Clinical Infectious Diseases (138)
  6. American Journal of Clinical Pathology (106)

More Publications

Results (4652)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • A phase I/II open-label study (IOV-GM1-201) of TALEN-mediated PD-1 inactivated autologous tumor-infiltrating lymphocytes (TIL; IOV-4001) in patients with advanced melanoma and NSCLC
    Meeting Abstract

    Chesney, J.; Wise-Draper, T.; Sarnaik, A. A.; Finckenstein, F. G.; Hari, P.; Jagasia, M.; Desai, A.; Suzuki, A.; Wu, X.; Warner, A. B.
    Annals of Oncology (2022)

    Fulltext@MSK | Save
  • Naxitamab treatment for relapsed or refractory high-risk neuroblastoma: Outcomes from the first prespecified analyses of the Pivotal 201 Trial
    Meeting Abstract

    Mora, J.; Bear, M.; Chan, G.; Morgenstern, D. A.; Nysom, K.; Tornøe, K.; Sørensen, P. S.; Kushner, B.
    Annals of Oncology (2022)

    Fulltext@MSK | Save
  • COMPOSE: Pivotal phase III trial to compare 177Lu-edotreotide with best standard of care for well-differentiated aggressive grade 2 and grade 3 gastroenteropancreatic neuroendocrine tumours
    Meeting Abstract

    Halfdanarson, T. R.; Halperin, D.; Reidy-Lagunes, D.; Kong, G.; Mailman, J.; Herrmann, K.; Sri Rajaskanthan, R.; Leyden, S.; Capdevila Castillon, J.; Sierras, C.; more...
    Annals of Oncology (2022)

    Fulltext@MSK | Save
  • A prospective study of a multi-cancer early detection blood test
    Meeting Abstract

    Schrag, D.; McDonnell, C. H. 3rd; Nadauld, L.; Dilaveri, C. A.; Klein, E. A.; Reid, R.; Marinac, C. R.; Chung, K. C.; Lopatin, M.; Fung, E. T.; more...
    Annals of Oncology (2022)

    Fulltext@MSK | Save
  • Long-term survivors on tebentafusp in phase II trial of previously treated patients with metastatic uveal melanoma
    Meeting Abstract

    Sato, T.; Ikeguchi, A. P.; Nathan, P.; Carvajal, R. D.; Shoushtari, A. N.; Gajewski, T. F.; Hassel, J. C.; Rioth, M.; Leyvraz, S.; Daniels, G. A.; more...
    Annals of Oncology (2022)

    Fulltext@MSK | Save
  • Phase II study of cemiplimab in patients with advanced cutaneous squamous cell carcinoma (CSCC): Final analysis from EMPOWER-CSCC-1 groups 1, 2 and 3
    Meeting Abstract

    Migden, M. R.; Schmults, C.; Khushanlani, N.; Guminski, A.; Chang, A. L.; Lewis, K.; Ansstas, G.; Bowyer, S. E.; Hughes, B. G. M.; Schadendorf, D.; more...
    Annals of Oncology (2022)

    Fulltext@MSK | Save
  • Safety and efficacy of infrequent tebentafusp treatment omissions in patients with metastatic uveal melanoma
    Meeting Abstract

    Schlaak, M.; Dummer, R.; Kirkwood, J. M.; Joshua, A.; Milhem, M.; Gastaud, L.; Mauch, C.; Yushak, M. L.; Lockwood, S.; Hayes, C.; more...
    Annals of Oncology (2022)

    Fulltext@MSK | Save
  • A propensity score weighted comparison of tebentafusp or pembrolizumab versus combination ipilimumab and nivolumab in untreated metastatic uveal melanoma
    Meeting Abstract

    Piulats Rodriguez, J. M.; Piperno-Neumann, S.; Rutkowski, P.; Nathan, P.; Hassel, J. C.; Espinosa, E.; de la Cruz Merino, L.; Ochsenreither, S.; Shoushtari, A. N.; Orloff, M.; more...
    Annals of Oncology (2022)

    Fulltext@MSK | Save
  • Results from phase I dose escalation of IMC-F106C, the first PRAME X CD3 ImmTAC bispecific protein in solid tumors
    Meeting Abstract

    Hamid, O.; Sato, T.; Davar, D.; Callahan, M. K.; Thistlethwaite, F.; Aljumaily, R.; Johnson, M. L.; Arkenau, H. T.; Ileana Dumbrava, E. E.; Izar, B.; more...
    Annals of Oncology (2022)

    Fulltext@MSK | Save
  • A phase I trial of the bifunctional EGFR/TGFb fusion protein BCA101 alone and in combination with pembrolizumab in patients with advanced solid tumors
    Meeting Abstract

    Hanna, G. J.; Hernando Calvo, A.; Morris, V.; Carvajal, R. D.; Paik, P. K.; Zandberg, D. P.; Kaczmar, J.; Niculescu, L.; Reiners, R.; Bohr, D.; more...
    Annals of Oncology (2022)

    Fulltext@MSK | Save